Evidence map›Paper›PMID 41097402›Full record

ReviewMolecules (Basel, Switzerland)2025

From Plants to Protection: Cardiorenal Benefits in Non-Diabetic Chronic Kidney Disease and Heart Failure.

Dan Claudiu Măgureanu, Raluca Maria Pop, Ioana Corina Bocsan, Maria Adriana Neag, Angela Cozma, Antonia Mihaela Levai, Veronica Sanda Chedea, Anca Dana Buzoianu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dan Claudiu MăgureanuPharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania.ORCID 0000-0003-4883-3856
Raluca Maria PopPharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania.ORCID 0000-0003-1899-5977
Ioana Corina BocsanPharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-3279-5384
Maria Adriana NeagPharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-3904-2852
Angela CozmaDepartment of Internal Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-3989-2291
Antonia Mihaela LevaiObstetrics and Gynecology, Department of Mother and Child, "Iuliu Hatieganu" University of Medicine and Pharmacy, Victor Babeș, No 8, 400012 Cluj-Napoca, Romania.
Veronica Sanda ChedeaResearch Station for Viticulture and Enology Blaj (SCDVV Blaj), 515400 Blaj, Romania.ORCID 0000-0002-7075-8867
Anca Dana BuzoianuPharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-3511-2788

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-diabetic chronic kidney disease (ND-CKD) refers to the progressive and irreversible decline in kidney function occurring in the absence of diabetes mellitus-a distinction that sets it apart from the more prevalent diabetic CKD. While diabetic nephropathy remains the leading cause of CKD globally, ND-CKD encompasses a heterogeneous group of etiologies, including hypertensive nephrosclerosis, glomerulonephritis, and interstitial nephritis. Its incidence and prevalence are steadily increasing, particularly in aging populations, and are often underrecognized. Importantly, ND-CKD is not a benign entity; it independently contributes to systemic inflammation, oxidative stress, and metabolic dysregulation, which in turn amplify cardiovascular risk. Among the most severe complications is heart failure (HF), a complex syndrome arising from structural and functional impairments in cardiac performance. Despite ongoing advancements in HF management, mortality remains unacceptably high, ranging from 2-3% at 30 days to up to 50-75% over five years. Standard pharmacologic therapies frequently fall short in halting disease progression and may provoke undesirable side effects. This therapeutic gap has spurred growing interest in natural compounds with multi-targeted effects. Bioactive molecules such as arjunolic acid, kaempferol, luteolin, and resveratrol have shown anti-inflammatory and antioxidant properties that may offer dual benefits for both renal and cardiac function. By modulating shared molecular pathways-including those involved in inflammation, oxidative damage, and cellular dysfunction-these agents hold promise as adjunctive treatments in ND-CKD complicated by heart failure.

Indexed as

Heart FailureRenal Insufficiency, ChronicAnimalsAntioxidantsHumansOxidative StressAntioxidantsheart failureinflammationnatural compoundsnon-diabetic chronic kidney diseaseoxidative stress

Identifiers

PMID41097402
PMCPMC12525604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.